Rosemary Mazanet, M.D., PhD. Joins Columbia Care's Board of Directors

Dr. Mazanet began advising Columbia Care in 2013 and then joined its Scientific Advisory Board as its Chair in 2015.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Monday, September 11, 2023
Information
Tags: 
Natural Resources, Alternative Medicine, Other Manufacturing, Health, Specialty, Cannabis, Manufacturing, Retail, Columbia University, University of Southern California, Heart, Database, University, Palliative care, Wharton School of the University of Pennsylvania, Journal of Palliative Medicine, Coronavirus Scientific Advisory Board, General partnership, Human, FSE, National Institutes of Health, Bangladesh Technical Education Board, Dana–Farber Cancer Institute, Harvard Medical School, Tablet, Leonard Davis Institute of Health Economics, Journal, RAND Corporation, Clinical research, Internal medicine, Filgrastim, Knowledge, Hospital, FDA, Dana, NEO, NLRB v. Kentucky River Community Care, Inc., Chair, JAMA, Pharmaceutical industry, Management, Amgen, New York University, Brigham
Geotags: 
NEW YORK, UNITED STATES, NORTH AMERICA, PENNSYLVANIA, VIRGINIA
⚠ partially generated by AI ↴
Organisation: 
COLUMBIA CARE, COLUMBIA CARE INC.
Stock Symbol: 
NEO:CCHW
OTCQX:CCHWF
FWB:3LP
Summary
Key Points: 
  • Dr. Mazanet began advising Columbia Care in 2013 and then joined its Scientific Advisory Board as its Chair in 2015.
  • Since 2013, she has played an integral role of developing groundbreaking form factors specifically for palliative care, such as pressed tablets.
  • I know she will continue to add significant value as a member of our Board of Directors.
  • Congratulations, Rosemary and thank you," said Nicholas Vita, CEO, Columbia Care.


Columbia Care Inc. (NEO: CCHW) (OTCQX: CCHWF) (FSE: 3LP) (“Columbia Care” or the “Company”), one of the largest and most experienced cultivators, manufacturers and retailers of cannabis products in the U.S., today announced the transition of Rosemary Mazanet, M.D., PhD., from Chief Scientific Officer, a role she has held since 2017, to a member of the Company’s Board of Directors, effective immediately.

Dr. Mazanet began advising Columbia Care in 2013 and then joined its Scientific Advisory Board as its Chair in 2015. Since 2013, she has played an integral role of developing groundbreaking form factors specifically for palliative care, such as pressed tablets. She also oversaw the creation of the seminal cannabis observational database that has provided analysis used in peer-reviewed journals, such as JAMA and the Journal of Palliative Medicine and by many of the nation’s leading academic and medical institutions such as National Institutes of Health, Columbia University, New York University, Mount Sinai, University of Southern California, and RAND Corporation. This database has also been used by policymakers at the federal and state level contributing to the development of cannabis policies that have advanced the industry. Following review and consideration, Dr. Mazanet was recommended for appointment by the Company’s Nominating and Governance Committee given her ability to contribute and add value to the Board based of her extensive medical, scientific, Company, industry, and public company experience.

"The consumers and communities we serve are always at the heart of what we do. Rosemary has been a leading voice and organizational leader as Columbia Care developed and evolved, while at the same time, serving as a pillar to ensure we maintained fidelity to our mission of improving peoples’ lives. We are grateful to her ongoing commitment as well as for the expertise and knowledge she has shared with us over the last decade. I know she will continue to add significant value as a member of our Board of Directors. Congratulations, Rosemary and thank you," said Nicholas Vita, CEO, Columbia Care.

Dr. Mazanet began her career in Internal Medicine and Oncology at the Brigham and Women’s Hospital and the Dana Farber Cancer Institute before starting at Amgen in the early 1990s as the head of Clinical Research. At Amgen, Dr. Mazanet held broad responsibilities as one of the first U.S. trained clinician scientists in her field, where she led multiple successful product development initiatives, including FDA panel presentations for groundbreaking stem-cell therapies such as Neupogen. Following her time at Amgen, she moved into public equity in 1998 when she joined Oracle Partners LLC in New York as a General Partner. Since that time, she has been a presence in public and private equity biotech and specialty pharma investments. In addition to the Columbia Care Board of Directors, Dr. Mazanet is also an Emeritus Trustee at the University of Pennsylvania School of Medicine and the Co-Chair of the Leonard Davis Institute Executive Advisory Board at The Wharton School of the University of Pennsylvania. Dr. Mazanet graduated magna cum laude from the University of Virginia and completed her graduate work at the University of Pennsylvania Medical School and Harvard Medical School.

About Columbia Care

Columbia Care is one of the largest and most experienced cultivators, manufacturers and providers of cannabis products and related services, with licenses in 16 U.S. jurisdictions. Columbia Care operates 125 facilities including 94 dispensaries and 31 cultivation and manufacturing facilities, including those under development. Columbia Care is one of the original multi-state providers of medical cannabis in the U.S. and now delivers industry-leading products and services to both the medical and adult-use markets. In 2021, the company launched Cannabist, its retail brand, creating a national dispensary network that leverages proprietary technology platforms. The company offers products spanning flower, edibles, oils and tablets, and manufactures popular brands including Seed & Strain, Triple Seven, Hedy, gLeaf, Classix, Press, and Amber. For more information on Columbia Care, please visit www.columbia.care.

Caution Concerning Forward Looking Statements

This press release contains certain statements that constitute “forward-looking information” or “forward-looking statements” within the meaning of applicable securities laws and reflect the Company’s current expectations regarding future events. Forward-looking statements or information contained in this release include, but are not limited to, statements or information with respect to the executive management transition. These forward-looking statements or information, which although considered reasonable by the Company, may prove to be incorrect and are subject to known and unknown risks and uncertainties that may cause actual results, performance or achievements of the Company to be materially different from those expressed or implied by any forward-looking information. In addition, securityholders should review the risk factors discussed under “Risk Factors” in Columbia Care’s Form 10-K for the year ended December 31, 2022, as, filed with Canadian and U.S. securities regulatory authorities and described from time to time in subsequent documents filed with applicable securities regulatory authorities.

Copyright: 
Copyright Business Wire 2023